Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.71 |
| ▸ | CTSD | P07339 | 15/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 15/20 | 0.60 |
| ▸ | REN | P00797 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109494 | 1.00 | BACE1 (0.71) | BACE1CTSDBACE2REN | |
| SCHEMBL4109618 | 0.92 | BACE1 (0.65) | BACE1CTSDBACE2REN | |
| SCHEMBL4907715 | 0.89 | BACE1 (0.73) | BACE1CTSDBACE2REN | |
| SCHEMBL4110039 | 0.89 | BACE1 (0.62) | BACE1CTSDBACE2REN | |
| SCHEMBL4102970 | 0.87 | BACE1 (0.75) | BACE1CTSDBACE2REN | |
| SCHEMBL8241101 | 0.86 | BACE1 (0.71) | BACE1CTSDBACE2REN | |
| SCHEMBL3531842 | 0.85 | BACE1 (0.82) | BACE1CTSDBACE2REN | |
| SCHEMBL3534398 | 0.85 | BACE1 (0.82) | BACE1CTSDBACE2REN | |
| SCHEMBL3536134 | 0.85 | BACE1 (0.82) | BACE1CTSDBACE2REN | |
| SCHEMBL4103867 | 0.85 | BACE1 (0.61) | BACE1CTSDBACE2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | BACE1 5/4885CTSD 354/4885BACE2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.